Particulars (Rs. in Crores) | Q2 FY23 | Q1FY23 | QOQ | Q2 FY22 | YOY |
---|---|---|---|---|---|
Revenue from Operations | 1044.40 | 856.89 | 21.88% | 1080.40 | -3.33% |
EBITDA | 297.20 | 269.92 | 10.00% | 376.70 | -21.00% |
PAT | 241.70 | 229.17 | 5.00% | 302.20 | -20.00% |
EPS | 14.65 | 13.93 | 5.17% | 18.37 | -20.25% |
Source: Company Filings; StockAxis Research
Q2 FY23 Highlights
Gland Pharma has posted good recovery across all parameters on QoQ basis. The revenue
for the quarter stood at Rs 1044 cr as compared to Q1 FY23 at Rs 857 cr, an increase
of 22%. EBITDA of the company stood at Rs 297 cr. during the quarter as compared
to Rs 270 cr. in Q1 FY23, an increase of 10%. However, company’s EBITDA witnessed
a downfall of 21% on YoY basis due to decline in top-line (on YoY basis) on account
of price erosion, delay in supply of raw material, increased employee cost as company
has added 400-500 employees during the quarter and increased freight cost. PAT for
the quarter stood at Rs 242 cr. as compared to Q1 FY23 at Rs 229, an increase of
5%. The EPS of the company witnessed a growth of 5% and accounted for Rs 14.65.
Revenue breakup geography-wise
Particulars | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
---|---|---|---|---|---|
USA, Europe, Canada, and Australia (Core Markets) | 747.5 | 722.5 | 3% | 705.6 | 6% |
India | 72.6 | 125.8 | -42% | 51 | -42% |
ROW | 224.3 | 232.2 | -3% | 100.2 | 12.40% |
TOTAL | 1044.4 | 1080.5 | -3% | 856.9 | 22% |
Key Concall Highlights
Gland Pharma has witnessed an improved performance for the quarter ended 30th September 2022 although during Q2 FY23 company’s sales were impacted by delay in restarting the insulin supply, absence of sales of Heparin, disruption in bag manufacturing as well as some delay in Lyo installations and lower than expected revenue from its oncology segment. Going forward we expect improved margins on account of smooth flow of supply chain and decrease in prices of raw materials, along with easing US market conditions. It’s major products such as Heparin and insulin supply will come into force. The company has a robust business model with diversified product portfolio with many products in the USFDA shortages list. Overall we remain positive on the stock .
As per CMP of Rs 2225.3 (as on 26th October 2022), as per our estimates the stock is trading at 23.1x of its FY 25E earnings.
We recommend ‘HOLD’ to the stock.
Particulars (Rs. in Crores) | Q2 FY23 | Q1FY23 | QOQ | Q2 FY22 | YOY |
---|---|---|---|---|---|
Revenue from Operations | 1044.40 | 856.90 | 21.88% | 1080.40 | -3.33% |
COGS | 519.30 | 374.05 | 524.00 | ||
Gross Profit | 525.10 | 482.84 | 556.40 | ||
Gross Margin (%) | 50.00% | 56.35% | 51.50% | ||
Employee Benefit Expenses | 101.20 | 98.00 | 82.30 | ||
Other Expenses | 126.70 | 114.92 | 97.40 | ||
EBITDA | 297.20 | 269.92 | 10.11% | 376.70 | -21.10% |
EBITDA Margin (%) | 28.00% | 31.50% | 34.87% | ||
Depreciation | 36.60 | 34.91 | 26.10 | ||
EBIT | 260.60 | 235.01 | 10.89% | 350.60 | -25.67% |
EBIT Margin (%) | 25.00% | 27.43% | 32.45% | ||
Finance Cost | 1.70 | 0.90 | 1.00 | ||
Oher Income | 65.60 | 74.39 | 51.10 | ||
Profit Before Exceptional Items & Tax | 324.50 | 308.50 | 400.70 | ||
Exceptional Items | - | - | - | ||
Profit Before Tax | 324.50 | 308.50 | 5.19% | 400.70 | -19.02% |
Tax | 82.80 | 79.33 | 98.50 | ||
Effective Tax Rate (%) | 26.00% | 25.71% | 24.58% | ||
Profit After Tax | 241.70 | 229.17 | 5.47% | 302.20 | -20.02% |
PAT Margin (%) | 23.00% | 26.74% | 27.97% | ||
Earnings Per Share (Rs.) | 14.65 | 13.93 | 5.17% | 18.37 | -20.25% |
Source: Company Filings; StockAxis Research
Year End March (Rs. in Crores) | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Net Sales | 3462.90 | 4400.70 | 4050.00 | 4900.00 | 5900.00 |
Growth % | 31.50% | 27.10% | -8.00% | 21.00% | 20.40% |
Expenditure | |||||
Material Cost | 1491.90 | 2109.30 | 1984.50 | 2303.00 | 2773.00 |
Employee Cost | 311.40 | 338.60 | 401.00 | 416.50 | 501.50 |
Other Expenses | 357.40 | 442.70 | 429.30 | 494.90 | 572.30 |
EBITDA | 1302.30 | 1510.20 | 1235.30 | 1685.60 | 2053.20 |
Growth % | 36.30% | 16.00% | -18.20% | 36.50% | 21.80% |
EBITDA Margin | 37.60% | 34.30% | 30.50% | 34.40% | 34.80% |
Depreciation & Amortization | 98.80 | 110.30 | 115.00 | 130.00 | 150.00 |
EBIT | 1203.50 | 1399.90 | 1120.30 | 1555.60 | 1903.20 |
EBIT Margin % | 34.80% | 31.80% | 27.70% | 31.70% | 32.30% |
Other Income | 134.80 | 223.90 | 181.20 | 221.00 | 222.00 |
Interest & Finance Charges | 3.40 | 5.20 | 5.00 | 5.00 | 6.00 |
Profit Before Tax - Before Exceptional | 1334.90 | 1618.50 | 1296.50 | 1771.60 | 2119.20 |
Profit Before Tax | 1334.90 | 1618.50 | 1296.50 | 1771.60 | 2119.20 |
Tax Expense | 337.80 | 406.90 | 326.30 | 445.90 | 534.00 |
Effective Tax rate | 25.30% | 25.10% | 25.20% | 25.20% | 25.20% |
Exceptional Items | - | - | - | - | - |
Net Profit | 997.00 | 1211.60 | 970.10 | 1325.70 | 1585.20 |
Growth % | 29.00% | 21.50% | -19.90% | 36.70% | 19.60% |
Net Profit Margin | 28.80% | 27.50% | 24.00% | 27.10% | 26.90% |
Consolidated Net Profit | 997.00 | 1211.60 | 970.10 | 1325.70 | 1585.20 |
Growth % | 29.00% | 21.50% | -19.90% | 36.70% | 19.60% |
Net Profit Margin after MI | 28.80% | 27.50% | 24.00% | 27.10% | 26.90% |
As of March (Rs. in Crores) | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Share Capital | 16.40 | 16.40 | 16.40 | 16.40 | 16.40 |
Total Reserves | 5861.50 | 7141.20 | 8016.50 | 9298.40 | 9189.50 |
Shareholders' Funds | 5903.30 | 7157.60 | 8032.90 | 9314.80 | 9205.90 |
Minority Interest | - | - | - | - | - |
Non Current Liabilities | |||||
Long Term Burrowing | 3.90 | 4.50 | 2.10 | 3.10 | 3.10 |
Deferred Tax Assets / Liabilities | 73.90 | 87.80 | 87.80 | 87.80 | 87.80 |
Long Term Provisions | - | - | - | - | - |
Current Liabilities | |||||
Short Term Borrowings | - | 0.30 | - | - | - |
Trade Payables | 400.70 | 462.90 | 474.60 | 514.90 | 562.20 |
Other Current Liabilities | 58.00 | 76.20 | 76.20 | 76.20 | 76.20 |
Short Term Provisions | 53.80 | 42.80 | 42.80 | 42.80 | 42.80 |
Total Equity & Liabilities | 6496.10 | 7833.90 | 8718.00 | 10042.00 | 10179.60 |
Assets | |||||
Net Block | 954.20 | 1701.90 | 1886.90 | 2106.90 | 2406.90 |
Non Current Investments | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 |
Long Term Loans & Advances | 78.00 | 83.60 | 83.60 | 83.60 | 83.60 |
Current Assets | |||||
Currents Investments | - | 154.90 | 200.00 | 200.00 | 200.00 |
Inventories | 1275.20 | 1185.70 | 1389.20 | 1287.30 | 1553.40 |
Sundry Debtors | 671.00 | 1198.80 | 1134.50 | 1103.40 | 1213.20 |
Cash and Bank | 3005.20 | 3093.40 | 3607.60 | 3114.40 | 2958.30 |
Short Term Loans and Advances | 87.60 | 0.50 | 0.50 | 0.50 | 0.50 |
Total Assets | 6496.10 | 7833.90 | 8718.07 | 10042.00 | 10179.40 |
Year End March (Rs. in Crores) | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Profit After Tax | 1334.90 | 1618.50 | 970.10 | 1325.70 | 1585.20 |
Depreciation | 98.80 | 110.30 | 115.00 | 130.00 | 150.00 |
Others | 0.70 | 38.00 | - | - | |
Changes in Working Capital | -435.80 | -338.10 | -127.40 | 173.20 | -327.60 |
Cash From Operating Activities | 604.90 | 790.70 | 707.70 | 1028.90 | 1107.60 |
Purchase of Fixed Assets | -228.80 | -511.00 | -300.00 | -350.00 | -450.00 |
Free Cash Flows | 376.20 | 279.70 | 407.70 | 678.90 | 657.60 |
Others | -1296.20 | -492.00 | - | - | - |
Cash Flow from Investing Activities | -1524.50 | -1002.60 | -300.00 | -350.00 | -450.00 |
Increase / (Decrease) in Loan Funds | -0.90 | -1.00 | -1.00 | 1.00 | -1.00 |
Equity Dividend Paid | - | - | - | - | |
Others | 1239.40 | 34.90 | - | - | |
Cash from Financing Activities | 1238.50 | 33.90 | -1.00 | 1.00 | -1.00 |
Net Cash Inflow / Outflow | 318.80 | -178.00 | 406.70 | 679.90 | 656.60 |
Opening Cash & Cash Equivalents | 169.50 | 488.30 | 310.40 | 717.10 | 1397.00 |
Closing Cash & Cash Equivalent | 488.30 | 310.40 | 717.10 | 1397.00 | 2053.60 |
Year End March | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Basic EPS | 60.70 | 73.70 | 59.00 | 80.70 | 96.50 |
Diluted EPS | 60.70 | 73.70 | 59.00 | 80.70 | 96.50 |
Cash EPS (Rs) | 66.70 | 80.50 | 66.00 | 88.60 | 105.60 |
DPS | - | - | - | - | |
Book value (Rs/share) | 359.30 | 435.70 | 488.90 | 566.90 | 560.30 |
ROCE (%) Post Tax | 20.90% | 18.60% | 12.80% | 15.30% | 17.20% |
ROE (%) | 16.90% | 16.90% | 12.10% | 14.20% | 17.20% |
Inventory Days | 107.10 | 102.00 | 116.00 | 100.00 | 88.00 |
Receivable Days | 67.10 | 78.00 | 105.00 | 83.00 | 72.00 |
Payable Days | 34.20 | 36.00 | 42.00 | 37.00 | 33.00 |
PE | 40.70 | 33.50 | 37.70 | 27.60 | 23.10 |
P/BV | 6.90 | 5.70 | 4.60 | 3.90 | 4.00 |
EV/EBITDA | 29.00 | 24.80 | 29.00 | 19.70 | 16.30 |
Dividend Yield (%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
P/Sales | 11.80 | 9.20 | 9.00 | 7.50 | 6.20 |
Net debt/Equity | - | - | - | - | - |
Net Debt/ EBITDA | -2.30 | -2.10 | -0.60 | -2.00 | 0.00 |
Sales/Net FA (x) | 3.60 | 3.30 | 2.30 | 2.50 | 2.60 |